ArticleNature communications2025
Chiral hypervalent iodine catalyzed stereoselective skeletal editing of pyrimidine fused heterocycles.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the realm of molecular construction, the skeletal editing techniques of heterocyclic compounds demonstrate unique efficiency, particularly in synthesizing molecular structures that are challenging to obtain through traditional synthetic methods. Compared to the ring-contraction reaction of saturated nitrogen heterocycles and aryl rings, the site selectivity and stereoselective skeletal editing of pyrimidine fused heterocycles remain relatively underdeveloped. Here we report a chiral hypervalent iodine(III)-catalyzed skeletal editing of pyrimidine moieties within polynitrogen heterocycles, which efficiently produces optically pure multi-substituted imidazoline rings. The reaction demonstrates exceptional functional group tolerance, as shown by the ring contraction of diverse polynitrogen heterocycles and the late-stage functionalization of M
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.